Wednesday, 16 Jan 2019

You are here

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not. This functional dimorphism allows for division into three groups: -21M/M, -21M/T and -21T/T with respectively decreasing potency of the NKCD94/NKG2A+ receptor. Dr. Chandran et al aimed to determine if these particular haplotypes served as differences between the connection between the HLA class 1 alleles and Psoriatic disease vs the normal population.

Six hundred and sixty four PsA patients, 1155 PsC (cutaneous only Psoriasis) patients vs 3118 controls were studied. One thousand one hundred and seventy seven PsA patients, 659 PsC patients and 1096 controls were self- reported European ethnicity from a single center cohort in Toronto. SNP2HLA was used represent HLA class 1 alleles. Analyses using logistical regression to determine association between HLA B-21 amino acid polymorphisms and different phenotypes in PsC vs controls, PsA vs controls, and PsA vs PsC. Sex and population stratification were used as covariates. This study used reverse line blot techniques and sequence specific oligonucleotide (SSO) probes to type HLA and all analyses were conditioned on HLA B27.

This study found that the PsC patient cohort had significantly lower prevalence of -21M compared to PsA and control patients.

In conclusion, this is one study that indicates a potential NK cell pathogenesis in the development of PsA and shows a possible genetic marker that can differentiate PsA from PsC.

Chandran V, Li Q, Machhar R, Abji F, Ye JY, Nair R, Stuart P, Oikonomopoulou K, Elder JT, Gladman DD, Rahman P. −21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/%e2%88%9221-hla-class-i-dimorphism-dif.... Accessed October 18, 2018.

 

https://acrabstracts.org/abstract/%E2%88%9221-hla-class-i-dimorphism-dif...

Add new comment

More Like This

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.